Dexamethasone Market

Introduction

Dexamethasone is corticosteroid drug used to treat many conditions like skin disease, rheumatic disease, lung disease, bowel disorders and certain cancers. Dexamethasone is an anti-inflammatory drug and hence reduces symptoms like allergy and swelling.

It also has properties like immunosuppression and can penetrate into the brain. Anti-inflammatory effects of Dexamethasone are complex in nature, but primarily the mechanism of action is via inhibition of inflammatory cells and suppression of inflammatory mediator expression. Dexamethasone systemic formulation is used in treatment of Addison's Disease, Allergic Rhinitis, Bronchopulmonary Dysplasia, Aspiration Pneumonia, Asthma, eczema, Psoriasis, Meningitis, ulcerative colitis, Neurosarcoidosis etc. Dexamethasone nasal formulation is used in treatment for nasal congestion.

Dexamethasone ophthalmic formulation is used for the treatment of Conjunctivitis, Iritis, Postoperative Ocular Inflammation Macular Edema and Keratitis. Dexamethasone otic formulation can be used for Otitis Externa and otitis media. Dexamethasone is also tested under clinical trials for conditions like supraclavicular block, pain caused post operation in patients under Periacetabular Osteotomy, Herpes Simplex Virus Encephalitis, Postoperative effects in IBD, Multiple myeloma, SARSCov-2 Infection. Few side effects of Dexamethasone include increased appetite, heartburn, insomnia and muscle weakness etc.

Dexamethasone market: Drivers and restraints

The factors such as global COVID-19 prevalence, growth in death rate, and authorization for emergency use of Dexamethasone for COVID-19 can be market drivers. Dexamethasone has proven to be a promising drug to treat COVID -19 pandemic emergency. The COVID-19 scenario is a very good opportunity for Local drug manufacturers. This is a major factor for the growth of Dexamethasone market.

The increase in the prices of active pharmaceutical ingredients (APIs) that are required to manufacture Dexamethasone can be a lucrative factor for pharma players as majority of the basic raw material comes from China. Dexamethasone in the form of oral, otic, ocular etc. can be used in treatment of a plethora of diseases and its increasing demand for this reason can lead to growth of the market.

Currently, with the escalation of COVID-19 pandemic, the healthcare systems are affected worldwide. Increasing preventive measures like vaccines under development can hamper the dexamethasone market in case of COVID-19. As valuable medical resources are diverted for addressing Covid-19 pandemic, the manufacturing process of Dexamethasone has come to halt. The manufacturers are facing challenges of ensuring access raw materials. The biggest worry of manufacturers are the supply of these drugs. This impact of COVID-19 can negatively affect Dexamethasone market.

Dexamethasone Market: Overview

The Anti-viral market industry is witnessing a dynamic growth owing to increasing viral diseases. It is reported that the global antiviral market is expected to grow by 46.9 USD billion by 2027. Around 2.8 million orders were released in June 2020 after the University of Oxford proved effect of Dexamethasone against COVID 19.

Improved survival rate in patients boosted up the demand for dexamethasone. Dexamethasone is an opportunistic drug and has become a breakthrough and a standard treatment for COVID-19 patients. Dexamethasone is available as both oral and injection. But injections are more popular in hospitals emergency wards. These injections are used for variety of treatments like allergies to swelling within brain etc.

It was reported that demand for Dexamethasone in June 2020 rose to 610%. Dexamethasone topical creams can be used for Eczema, Acne, Psoriasis and ionothophresis. Dexamethasone can also be used in combination with other drugs to treat many other disease conditions. Example being combination with Remdesivir. Because both Dexamethasone and Remdesivir have different mechanisms of action, the combination of both these drugs could be complimentary. In case of COVID-19, Remdesivir has shown to decrease damage due to the virus and dexamethasone has shown to slow down the damage caused by a hyper-inflammatory state.

Dexamethasone Market: Region-wise Outlook

UK are leading in Dexamethasone market. Dexamethasone was the first treatment to show reduction in mortality rate in patients infected with corona virus. Dexamethasone has been listed as an essential drug by the WHO. The UK government had stockpiled around 200,000 as reported by the NHS that can made available to the patients.

WHO has permitted for further trials of Dexamethasone in COVID-19. In UK, Studies were conducted to illustrate that Dexamethasone lowered mortality. The death rate came down by three and five times in patients on ventilators and patients on oxygen respectively. The demand for dexamethasone was seen to increasing highly in 2020 due to the pandemic. Many Pharma companies have started manufacturing generic drug Dexamethasone for meeting up the pandemic demand.

Dexamethasone Key Market players:

The key participants operating in the Dexamethasone market are Allergan plc, Alcon, Pfizer Inc, Morepan laboratories Ltd , Zydus Cadila, Aspen, Cadila Pharmaceuticals, GLS Pharma Ltd, Hikma Pharmaceuticals PLC, Merck and Co, Inc., Xspire Pharma, LLC, Taro Pharmaceutical Industries Ltd, Pragma Pharmaceuticals, LLC, Trotwood Pharma Limited, Wellona pharma, Wokhardt, Sandoz AG and AdvaCare Pharma.

The research report on Dexamethasone presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report on Dexamethasone provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on:

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain

Regional analysis includes:

• North America (U.S., Canada)
• Latin America (Mexico. Brazil)
• Western Europe (Germany, Italy, France, U.K, Spain)
• Eastern Europe (Poland, Russia)
• Asia Pacific (India, ASEAN, Australia & New Zealand)
• China
• Japan
• Middle East and Africa (GCC Countries, S. Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

• Detailed overview of parent market
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical, current, and projected market size in terms of volume and value
• Recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments, geographical regions exhibiting promising growth
• A neutral perspective on market performance
• Must-have information for market players to sustain and enhance their market footprint

Dexamethasone market: Segmentation

The global Dexamethasone market is segmented based on the type of route of administration, application, distribution channels and region.

By route of administration dexamethasone market is segmented as:

• Nasal
• Ophthalmic
• Otic
• Topical
• Oral
• Injectable

By application dexamethasone market is segmented as:

• Rheumatoid arthritis
• Psoriasis
• Eczema
• Pulmonary diseases
• COVID-19

By distribution channel dexamethasone market is segmented as:

• Hospital pharmacies
• Online pharmacies
• Retail stores